NEW YORK, NY--(Marketwire -03\/28\/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX - News) and Dendreon Corporation (NASDAQ: DNDN - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.fivestarequities.com\/IDIX<\/a> http:\/\/www.fivestarequities.com\/DNDN<\/a> <\/p>\n The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an \"on-ramp\" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. <\/p>\n Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.fivestarequities.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and Europe. Earlier this month the company announced that the United States Patent and Trademark Office (USPTO) declared a patent interference between Idenix's U.S. Patent Application no. 12\/131,868 and Pharmasset Inc.'s (acquired by Gilead Sciences) U.S. Patent no. 7,429,572, both related to certain nucleoside compounds useful in treating patients with hepatitis C virus (HCV) infection. <\/p>\n Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. <\/p>\n Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.fivestarequities.com\/disclaimer<\/a> <\/p>\n<\/p>\n Excerpt from: NEW YORK, NY--(Marketwire -03\/28\/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Idenix Pharmaceuticals Inc. Continue reading
\nIdenix Pharmaceuticals and Dendreon Benefit From Positive Decisions Out of Congress<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"